Artwork

Content provided by ResearchPod. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ResearchPod or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Discovery of new HER2 inhibitors offers hope for treatment of non-small cell lung cancer

10:19
 
Share
 

Manage episode 358022326 series 2680968
Content provided by ResearchPod. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ResearchPod or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Lung cancer accounts for one of the highest numbers of cancer related deaths, and - among its disease subtypes - HER2 mutations can play a key role in tumour initiation and growth. Unfortunately no targeted therapy is yet available to treat the most common HER2 mutations.

Dr Birgit Wilding, Dr Ralph Neumueller, Dr Flavio Solca, and colleagues at Boehringer Ingelheim have been researching these HER2 mutations, and have developed drugs that inhibit the abnormal HER2 signalling driving cancer growth. One of the new inhibitors is now undergoing testing in a Phase 1 clinical trial to safely assess the potential of the drug as effective against tumours, and also reducing side-effects.

Read the original research : https://doi.org/10.1038/s43018-022-00412-y

  continue reading

354 episodes

Artwork
iconShare
 
Manage episode 358022326 series 2680968
Content provided by ResearchPod. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ResearchPod or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Lung cancer accounts for one of the highest numbers of cancer related deaths, and - among its disease subtypes - HER2 mutations can play a key role in tumour initiation and growth. Unfortunately no targeted therapy is yet available to treat the most common HER2 mutations.

Dr Birgit Wilding, Dr Ralph Neumueller, Dr Flavio Solca, and colleagues at Boehringer Ingelheim have been researching these HER2 mutations, and have developed drugs that inhibit the abnormal HER2 signalling driving cancer growth. One of the new inhibitors is now undergoing testing in a Phase 1 clinical trial to safely assess the potential of the drug as effective against tumours, and also reducing side-effects.

Read the original research : https://doi.org/10.1038/s43018-022-00412-y

  continue reading

354 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide